ArticleClinical and molecular hepatology2020
Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.
Ankita Makol et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
16 papers cite it
this papercites it